Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274926 | 0.83 | CASP1 (0.45) | ALDH1A1GAAGSK3AGSK3BNPC1 | |
| SCHEMBL17274878 | 0.82 | MEN1 (0.51) | ALDH1A1ACHEBCHEGSK3AGSK3B | |
| SCHEMBL17275513 | 0.82 | NPC1 (0.56) | ALDH1A1ACHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2628367 | 0.79 | ACHE (0.56) | ALDH1A1ACHEGAAL3MBTL1BCHE | |
| SCHEMBL17274801 | 0.77 | CBFB (0.46) | GAACBFBMEN1KMT2AKIF11 | |
| SCHEMBL8832028 | 0.76 | NPC1 (0.65) | ALDH1A1GAAL3MBTL1GSK3AGSK3B | |
| SCHEMBL28280007 | 0.72 | ACHE (0.54) | ALDH1A1ACHEGAAL3MBTL1BCHE | |
| SCHEMBL2628332 | 0.70 | GABRA1 (0.56) | ALDH1A1ACHEBCHEGSK3AGSK3B | |
| SCHEMBL2958472 | 0.69 | SMN1; SMN2 (0.42) | ALDH1A1ACHEGAAL3MBTL1BCHE | |
| SCHEMBL17275512 | 0.69 | PDE3B (0.46) | ALDH1A1GAAL3MBTL1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | claimed |
| EP-3145507-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | Musc Foundation for Research Development (US) | 2017-03-29 | — | — | EP | claimed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | claimed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | claimed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2017-03-23 | — | — | US | disclosed |
| WO-2015179218-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081328-A1 | AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT | AZI2, DNMT1, TET3 | ALDH1A1 569/4885ACHE 1472/4885GAA 558/4885 |
| US-10456400-B2 | Aza-ellipticine analogs, methods of synthesis and methods of treatment | AZI2, DNMT1, TET3 | ALDH1A1 569/4885ACHE 1472/4885GAA 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.